IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

FDA issues import alert against Ranbaxy plant

7:28 AM MDT | September 17, 2013 | Deepti Ramesh

On 16 September, FDA issued an import alert for a Ranbaxy Laboratories (Gurgaon, India) facility at Mohali, India, for violating US drug cGMP requirements. Under the alert, US officials may detain at the US border drug products manufactured at the Mohali facility, and the company will remain on the import alert until it complies with cGMP, FDA says. FDA says it does not anticipate that this action will cause a supply disruption or shortage of drugs in the United States. FDA inspections, in September and December 2012, identified significant cGMP violations...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2014 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa